Tyler Menichiello
Tyler Menichiello is a contributing editor to Bioprocess Online, Cell & Gene, and Clinical Leader. He interviews executives and subject matter experts across the biopharma industry to write about their successful approaches in biologics development from pre-IND planning all the way through trial design, manufacturing, and commercialization. He aims to investigate the industry’s most prevalent challenges and emerging best practices to provide both interesting and actionable content for industry leaders. Prior to writing for Life Science Connect, Tyler spent two years as a clinical research associate at the University of Pittsburgh Medical Center’s (UPMC) Hillman Cancer Center, where he worked on clinical trials involving hematological malignancies. He studied biology and journalism at Indiana University of Pennsylvania (IUP). You can email Tyler at tyler.menichiello@lifescienceconnect.com, or visit his LinkedIn profile.
ARTICLES BY TYLER MENICHIELLO
-
![Pharmaceutical Production-GettyImages-2198724417]( "Experts' Advice On Facility Design And Construction")
Experts' Advice On Facility Design And Construction4/24/2025This is a review of the Pharmaceutical Online Live event “Facility Design And Validation Considerations For Drug Manufacturers," which featured industry experts Erich Bozenhardt and Herman Bozenhardt, as well as process architect Fred Grossfeld.
-
![Teamwork, communication strategy, management-GettyImages-1818579811]( "From BPI West: A Roundtable Discussion On Continuous Manufacturing")
From BPI West: A Roundtable Discussion On Continuous Manufacturing4/14/2025Process Development experts share their thoughts on continuous manufacturing at this year's BPI West, touching on its benefits and present barriers to adoption.
-
![Creative Ideas-GettyImages-2056470675]( "From BPI West: Key Challenges And Benefits Of Continuous Manufacturing")
From BPI West: Key Challenges And Benefits Of Continuous Manufacturing4/7/2025Continuous manufacturing was a hot topic of conversation at this year's BPI West. AstraZeneca's Ken Lee, Ph.D., weighs in during an exclusive interview with Bioprocess Online.
-
![Cell Culture-GettyImages-1435395022]( "From BPI West: An Upstream Scientist's Advice On Target Glycosylation")
From BPI West: An Upstream Scientist's Advice On Target Glycosylation4/1/2025Bioprocess Online spoke to an upstream scientist at Bristol Myers Squibb during this year's BPI West. Here's what he had to say.
-
![Human Cell-GettyImages-1533148452]( "2025 Cell Therapy Outlook From BPI West")
2025 Cell Therapy Outlook From BPI West3/31/2025Bioprocess Online and Cell & Gene spoke with Takeda’s Amy Shaw at BPI West to discuss the industry and her key takeaways from the conference.
-
![Coronavirus, covid structure-GettyImages-1356006431]( "Using AI And ML To Gain Insight Into Optimal Glycoforms")
Using AI And ML To Gain Insight Into Optimal Glycoforms3/28/2025Bioprocess Online asked Nathan Lewis, Ph.D., to briefly explain the research he presented at BPI West 2025.
-
![San Diego Convention Center]( "Impressions And Takeaways From BPI West 2025")
Impressions And Takeaways From BPI West 20253/27/2025Editor Tyler Menichiello reviews the most compelling topics and sessions from this year's BioProcess International U.S. West.
-
![business way-GettyImages-2075742031]( "Areas For Advancement In Peptide Manufacturing")
Areas For Advancement In Peptide Manufacturing2/27/2025Experts from Eli Lilly, NervGen, and Piramal Pharma Solutions discuss the myriad of ways peptide manufacturing can be improved, drawing on years of industry experience and insight.
-
![Environmentall Friendly-GettyImages-1341843646]( "For Gilead, Sustainability Is More Than A PR Effort")
For Gilead, Sustainability Is More Than A PR Effort2/14/2025Gilead's chief sustainability officer and SVP of operations, Joydeep Ganguly, explains the company's cultural focus on sustainability and how it influences everything from R&D to manufacturing.
-
![Antibodies-GettyImages-1409877704]( "GlycoNex On Challenges In Biosimilar Development, Manufacturing")
GlycoNex On Challenges In Biosimilar Development, Manufacturing1/29/2025In this written Q&A, GlycoNex president and CEO, Dr. Mei-Chun Yang, shares insight into the company's development of its denosumab biosimilar, SPD8. She covers the company’s approach to analytics, cell line development, scaling, and more.
